Breast cancer remains one of the most common types of cancer affecting women worldwide. Early detection is key to successful treatment and improved survival rates.
One of the most valuable tools in early diagnosis is biomarker testing, a method that analyzes the molecular characteristics of cancer cells. This approach enables doctors to tailor treatments and improve patient outcomes.
Understanding Biomarker Testing in Breast Cancer
Biomarker testing refers to the process of identifying specific molecules, or biomarkers, in the body that indicate the presence, type, and progression of breast cancer.
These biomarkers can include proteins, genes, and other molecules found in blood or tissue samples that help doctors understand the biology of a patient’s cancer. By determining the unique characteristics of a tumor, doctors can decide on the most appropriate treatment plan for the patient.
Types of Biomarkers in Breast Cancer
Several key biomarkers are commonly tested when diagnosing and managing breast cancer. These include:
- Hormone receptors (ER, PR): Estrogen receptor (ER) and progesterone receptor (PR) are proteins found on the surface of some breast cancer cells. When these receptors are present, the cancer is termed hormone receptor-positive, which means it may respond well to hormone therapy. Testing for these markers helps determine if drugs like tamoxifen or aromatase inhibitors could be effective treatment options.
- HER2 status: HER2 (human epidermal growth factor receptor 2) is a protein that promotes the growth of cancer cells. Cancers that overexpress HER2 are called HER2-positive. This biomarker helps guide treatment with drugs specifically designed to target HER2, such as trastuzumab (Herceptin) or pertuzumab.
Testing for these biomarkers allows oncologists to better classify the tumor and design a more targeted treatment approach. Importantly, early testing for these biomarkers can lead to quicker interventions, potentially saving lives.
Breast Cancer Biomarker Tests that are done on some tumors
Doctors also test for different breast cancer tumors for other biomarkers, but not all of these tests are done on every breast cancer. There are multiple variations of the HER2 gene that have too much HER2 protein, which makes breast cells grow and divide uncontrollably.
- PD-L1 status
If diagnosed with advanced-stage breast cancer, your doctor may test the cancer for PD-L1 positive to find out if the immunotherapy medicine Keytruda will be useful for you or not.
- Genomic Testing
Also known as genomic profiling, it is usually done in the early stages of breast cancer to figure out the chances of recurrence risk. If the chances are high, then chemotherapy or hormone therapy is recommended.
- ESR1 mutation status
This gene tells if your body makes estrogen receptors. If the receptors are positive, then breast cancer grows in the presence of estrogen. Estrogen receptor-positive breast cancer develops a type of mutation in the ESR1 gene during hormone therapy.
- PIK3CA mutation status
The PIK3CA gene tells your body whether it creates the PIK3 protein that helps ensure cells get the necessary energy to grow. When this gene is muted, the instructions given to your body by them are wrong.
- BRCA1 and BRCA2
If it is proven to be HER2-negative breast cancer, then it is certain that it is a BRCA1 and BRCA2 gene mutation, then the medicines Lynparza or even Talzenna can be recommended.
The Role of Biomarker Testing in Guiding Treatment Decisions
The greatest benefit of biomarker testing is its ability to shape personalized treatment plans. Breast cancer is a diverse disease, and not all cases should be treated the same way. Biomarkers offer critical information that helps doctors match the right therapy to each patient’s specific type of cancer.
For example, hormone receptor-positive breast cancers are often treated with hormone therapy, which helps to block the body’s natural hormones from fueling cancer growth. HER2-positive cancers, on the other hand, require HER2-targeted therapies to stop the spread of cancer cells.
Beyond guiding treatment decisions, biomarker testing can also prevent unnecessary treatments. Some breast cancers are slow-growing and may not require aggressive interventions like chemotherapy.
Finally, biomarkers aren’t only used for initial treatment decisions. They also help monitor disease progression. If a tumor’s characteristics change over time or if there are signs of recurrence, repeated biomarker testing can help adjust the treatment plan as needed.
TK Testing in Early Breast Cancer Diagnosis
A particularly interesting advancement in the field of biomarker testing is TK testing. TK, or thymidine kinase, is an enzyme involved in DNA synthesis and cell proliferation. Cancer cells, particularly those that are rapidly dividing, show higher levels of TK activity. This makes TK a useful biomarker for detecting aggressive tumors.
TK testing can be especially beneficial in early breast cancer diagnosis because it helps differentiate between slower-growing tumors and those that are likely to spread more quickly.
The Impact of Biomarker Testing on Patient Outcomes
The introduction of biomarker testing has revolutionized breast cancer treatment and significantly improved patient outcomes. By enabling more precise diagnoses and tailored treatments, biomarkers have contributed to higher survival rates and better quality of life for breast cancer patients.
- Improved Survival Rates
When breast cancer is caught early through biomarker testing, patients are more likely to survive long-term. For instance, the availability of HER2-targeted therapies for HER2-positive breast cancers has dramatically increased survival rates in this group.
Similarly, hormone therapies have proven highly effective for patients with hormone receptor-positive cancers, reducing the risk of recurrence.
- Quality of Life
Not only does biomarker testing improve survival, but it also helps patients avoid the unnecessary side effects of treatments that may not be needed.
By accurately identifying the characteristics of a tumor, doctors can limit the use of more toxic treatments, such as chemotherapy, when less aggressive options might suffice.
Breast Cancer Biomarker Testing Cost
The biomarker testing for breast cancer has a wide range of price variations depending on the type of tests and your insurance.
- Biomarker tests that are done depend primarily on the characteristics of cancer that are often not covered by insurance.
- Biomarker tests are done on every type of breast cancer that is covered by insurance.
- Biomarker tests that are not covered under insurance are still under investigation.
- For people who are diagnosed with metastatic cancer, then some of the biomarker tests are covered by Medicare and Medicaid.
Wrapping Up!
Biomarker testing is an essential tool in the fight against breast cancer, offering critical insights that guide treatment decisions and improve patient outcomes.
Whether through hormone receptor testing, HER2 analysis, or newer methods like TK testing, biomarker testing allows for a more targeted approach to breast cancer treatment. Early detection and personalized care remain the best strategies for improving survival rates and quality of life for breast cancer patients.
Also read